Oncoxin nutritional supplement in the management of chemotherapy- and/or radiotherapy-associated oral mucositis
- Authors:
- Alexandr Shumsky
- Evgeniy Bilan
- Eduardo Sanz
- Fedor Petrovskiy
View Affiliations
Affiliations: Medical Scientific Centre of Professor Shumsky, 443303 Samara, Russia, Khanty-Mansiysk Regional Hospital, 628011 Khanty-Mansiysk, Russia, Catalysis S.L., 28016 Madrid, Spain, Khanty-Mansiysk State Medical Academy, 628011 Khanty-Mansiysk, Russia
- Published online on: February 14, 2019 https://doi.org/10.3892/mco.2019.1809
-
Pages:
463-468
-
Copyright : © Shumsky
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License [CC BY 4.0].
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Oral mucositis (OM) is a common and potentially dangerous complication of anticancer treatment. Since there are only few therapeutic options for OM, there is a need to identify novel approaches to its management and prevention. The aim of the present study was to evaluate the efficacy of Oncoxin (ONCX), a nutritional supplement that contains microelements, vitamins, amino acids and certain biologically active substances of natural origin, in cancer patients who receive chemotherapy, radiotherapy or a combination of the two. A total of 15 male and female patients (aged 45‑75 years) with malignant neoplasms, who had been prescribed radiotherapy, chemotherapy or a combination of the two, with an Eastern Cooperative Oncology Group performance status score ≤3, and grade 2‑3 OM based on the World Health Organization (WHO) Oral Toxicity Scale, were enrolled in a 20‑day study; 10 patients were in the ONCX group and 5 served as controls. The patients were allowed to use any anticancer treatment and any type of OM care. In addition to their current treatment, patients in the ONCX group used 25 ml of the ONCX nutritional supplement twice daily for 20 days. The mean WHO Oral Toxicity Scale grade decreased by 41% in the ONCX group after ~7 days from the beginning of the study compared with minimal change in the control group. At the end of the study, the difference was even more prominent, with a 73 and 20% decrease from baseline in the ONCX and control groups, respectively (P<0.001). During the entire trial period, patients in the ONCX group were able to eat normally during 65% of the time, in contrast to only 29% in the control group (P=0.04). There were no statistically significant changes in absolute body mass, or in the number of days with normal appetite. This was a pilot study aiming to show the benefits of the ONCX nutritional supplement in OM, and the results demonstrated that ONCX rapidly improved the symptoms of OM and helped to maintain normal eating habits in patients undergoing cancer treatment.
View References
1
|
Shumsky AV: Pathology of oral cavity
induced by chemotherapy and radiotherapy in oncology patients.
Oncology for Dentists. Stomatology for Oncologists. Vse pravilno:
Moscow: pp. 234–246. 2016
|
2
|
Lalla RV, Sonis ST and Peterson DE:
Management of oral mucositis in patients who have cancer. Dent Clin
North Am. 5261–77. (viii)2008. View Article : Google Scholar : PubMed/NCBI
|
3
|
Campos MI, Campos CN, Aarestrup FM and
Aarestrup BJ: Oral mucositis in cancer treatment: Natural history,
prevention and treatment. Mol Clin Oncol. 2:337–340. 2014.
View Article : Google Scholar : PubMed/NCBI
|
4
|
Wardley AM, Jayson GC, Swindell R,
Morgenstern GR, Chang J, Bloor R, Fraser CJ and Scarffe JH:
Prospective evaluation of oral mucositis in patients receiving
myeloablative conditioning regimens and haemopoietic progenitor
rescue. Br J Haematol. 110:292–299. 2000. View Article : Google Scholar : PubMed/NCBI
|
5
|
Al-Mahtab M, Akbar SM, Khan MS and Rahman
S: Increased survival of patients with end-stage hepatocellular
carcinoma due to intake of ONCOXIN®, a dietary
supplement. Indian J Cancer. 52:443–446. 2015. View Article : Google Scholar : PubMed/NCBI
|
6
|
Dzhugashvili M, Pokrovsky VS and Snegovoy
AV: Novel approaches for the correction of micronutrient deficiency
in patients with malignant tumors. Malignant Tumours. 2:55–65.
2016.
|
7
|
Zhao H, Zhu W, Xie P, Li H, Zhang X, Sun
X, Yu J and Xing L: A phase I study of concurrent chemotherapy and
thoracic radiotherapy with oral epigallocatechin-3-gallate
protection in patients with locally advanced stage III
non-small-cell lung cancer. Radiother Oncol. 110:132–136. 2014.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Zhao H, Xie P, Li X, Zhu W, Sun X, Sun X,
Chen X, Xing L and Yu J: A prospective phase II trial of EGCG in
treatment of acute radiation-induced esophagitis for stage III lung
cancer. Radiother Oncol. 114:351–356. 2015. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kantor ED, Lampe JW, Navarro SL, Song X,
Milne GL and White E: Associations between glucosamine and
chondroitin supplement use and biomarkers of systemic inflammation.
J Altern Complement Med. 20:479–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
10
|
Bak YK, Lampe JW and Sung MK: Effects of
dietary supplementation of glucosamine sulfate on intestinal
inflammation in a mouse model of experimental colitis. J
Gastroenterol Hepatol. 29:957–963. 2014. View Article : Google Scholar : PubMed/NCBI
|
11
|
Prasad AS, Beck FWJ, Bao B, Fitzgerald JT,
Snell DC, Steinberg JD and Cardozo LJ: Zinc supplementation
decreases incidence of infections in the elderly: Effect of zinc on
generation of cytokines and oxidative stress. Am J Clin Nutr.
85:837–844. 2007. View Article : Google Scholar : PubMed/NCBI
|
12
|
Akimoto M, Kimura M, Sawano A, Iwasaki H,
Nakajima Y, Matano S and Kasai M: Prevention of cancer
chemotherapeutic agent-induced toxicity in postoperative breast
cancer patients with glycyrrhizin (SNMC). Gan No Rinsho.
32:869–872. 1986.(In Japanese). PubMed/NCBI
|
13
|
Yan Y, Mo Y and Zhang D: Magnesium
isoglycyrrhizinate prevention of chemotherapy-induced liver damage
during initial treatment of patients with gastrointestinal tumors.
Zhonghua Gan Zang Bing Za Zhi. 23:204–208. 2015.(In Chinese).
PubMed/NCBI
|
14
|
Consolo LZ, Melnikov P, Cônsolo FZ,
Nascimento VA and Pontes JC: Zinc supplementation in children and
adolescents with acute leukemia. Eur J Clin Nutr. 67:1056–1059.
2013. View Article : Google Scholar : PubMed/NCBI
|
15
|
Ames BN: DNA damage from micronutrient
deficiencies is likely to be a major cause of cancer. Mutat Res.
475:7–20. 2001. View Article : Google Scholar : PubMed/NCBI
|